Dogwood announces interim Phase 2b trial results on Halneuron

Dogwood (DWTX) Therapeutics announced results from an interim analysis of 97 patients who had completed treatment in the ongoing Halneuron Phase 2b chemotherapy induced neuropathic pain study. The independent statistical review committee reviewed unblinded patient treatment data from the Phase 2b trial and concluded that Halneuron treated patients are demonstrating separation from placebo treated patients in terms of pain improvement over the four-week study. Based on the current Phase 2b trial enrollment pace and the interim assessment results, the Company continues to expect to have top-line results available during Q3 2026. Current study patient enrollment trends are projected to provide statistical power of approximately 80% to 85% to detect a Halneuron treatment difference. This preliminary evidence of a Halneuron treatment effect is noteworthy as patients in the interim analysis population present an average duration of CINP of 5 years and 67% of patients that met entry criteria were also being treated with stable doses of other chronic pain medicines, including pregabalin, gabapentin, duloxetine, and opioids. In addition, the overall study dropout rate of approximately 4.4% is far below rates typically observed with other FDA approved chronic pain medicines. While still blinded, the Company believes these findings reaffirm the encouraging safety and tolerability profile of Halneuron observed in previous clinical trials.